Comparable Clinical Outcome Using Small or Large Gross Tumor Volume-to-Clinical Target Volume Margin Expansion in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Table 2
Patterns of recurrence.
Site of recurrence
Small margin group (N = 37)
Large margin group (N = 102)
value
Any recurrence
18 (48.6%)
56 (54.9%)
0.645
Local recurrence
4 (10.8%)
7 (6.9%)
0.684
Regional recurrence
11 (29.7%)
35 (34.3%)
0.761
In-field recurrence
7 (18.9%)
22 (21.6%)
0.917
In-field recurrence without out-field recurrence
1 (2.7%)
15 (14.7%)
0.097
Out-field recurrence
10 (27.0%)
20 (19.6%)
0.480
Out-field recurrence without in-field recurrence
4 (10.8%)
13 (12.7%)
0.988
In-field and out-field recurrences
6 (16.2%)
7 (6.9%)
0.179
Distant metastasis
16 (43.2%)
51 (50.0%)
0.608
Lung
10 (27.0%)
30 (29.4%)
0.950
Nonregional lymph node
5 (13.5%)
22 (21.6%)
0.413
Supraclavicular fossa
3 (8.1%)
16 (15.7%)
0.384
Neck
2 (5.4%)
9 (8.8%)
0.761
Intra-abdominal
2 (5.4%)
9 (8.8%)
0.761
Axilla
2 (5.4%)
1 (1.0%)
0.354
Liver
4 (10.8%)
16 (15.7%)
0.652
Bone
2 (5.4%)
12 (11.8%)
0.434
Pleural seeding
2 (5.4%)
8 (7.8%)
0.904
Others
5† (13.5%)
13‡ (12.7%)
1.000
†Adrenal gland = 2, kidney = 2, and hypopharynx = 1. ‡Peritoneal seeding = 5, adrenal gland = 3, kidney = 3, pancreas = 2, hypopharynx = 1, brain = 1, cecum = 1, and psoas muscle = 1. One patient had both peritoneal seeding and pancreatic metastasis, and another patient had both adrenal and cecal metastasis. One patient had peritoneal, renal, and psoas muscle metastasis.
